Taran Therapeutics

Executive Summary

Taran Therapeutics is a private biotechnology company headquartered in San Diego, CA, focused on developing LENZ, a novel biologic (antibody) candidate for the treatment of serious and life-threatening leukemias and associated myeloid conditions. LENZ is positioned as a potential valuable medicine addressing a significant unmet need in hematologic malignancies, particularly those arising from prior chemotherapy. The company is advancing LENZ toward regulatory approval, targeting both frontline and post-chemotherapy settings, which could expand its addressable patient population. With a strong scientific rationale and late-stage clinical development, Taran aims to bring a new therapeutic option to patients with limited alternatives. The company is currently in Phase 3 development and is preparing to approach regulatory authorities for marketing approval. Key upcoming milestones include the submission of a Biologics License Application (BLA) to the FDA, followed by potential priority review and approval decisions. Additionally, Taran is exploring the expansion of LENZ into other myeloid conditions linked to prior chemotherapy, which could unlock further value. While LENZ has not yet been approved, its late-stage status and clear regulatory pathway position Taran as a compelling player in the oncology biologics space.

Upcoming Catalysts (preview)

• Q3 2026BLA/NDA Submission for LENZ in Lead Indication80% success
• Q1 2027FDA Decision on Marketing Approval60% success
• Q4 2026Initiation of Phase 2 Study in Post-Chemotherapy Myeloid Conditions70% success